Last reviewed 2026-05-18 · How we verify

ARCT-021 Dose Regimen 2

Arcturus Therapeutics, Inc. · Phase 1 active Biologic Quality 10/100

ARCT-021 Dose Regimen 2 is a Biologic drug developed by Arcturus Therapeutics, Inc.. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ARCT-021 Dose Regimen 2
Sponsor	Arcturus Therapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARCT-021 Dose Regimen 2 CI brief — competitive landscape report
ARCT-021 Dose Regimen 2 updates RSS · CI watch RSS
Arcturus Therapeutics, Inc. portfolio CI

Frequently asked questions about ARCT-021 Dose Regimen 2

What is ARCT-021 Dose Regimen 2?

ARCT-021 Dose Regimen 2 is a Biologic drug developed by Arcturus Therapeutics, Inc..

Who makes ARCT-021 Dose Regimen 2?

ARCT-021 Dose Regimen 2 is developed by Arcturus Therapeutics, Inc. (see full Arcturus Therapeutics, Inc. pipeline at /company/arcturus-therapeutics-inc).

What development phase is ARCT-021 Dose Regimen 2 in?

ARCT-021 Dose Regimen 2 is in Phase 1.

Manufacturer: Arcturus Therapeutics, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing